Sep 29, 2026 05:53PM

Sep 29, 2026 05:52PM

Sep 17, 2026 05:06PM

Sep 17, 2026 05:05PM

Sep 9, 2026 02:33PM

Sep 9, 2026 02:32PM

Aug 19, 2026 01:07PM Marvel Biosciences extends private placement to Quebec investors

Aug 19, 2026 01:06PM

Jul 16, 2026 04:01PM

Jul 16, 2026 04:00PM

Apr 7, 2026 07:37AM

Mar 18, 2026 07:02AM

Mar 18, 2026 07:00AM

Mar 4, 2026 07:00AM Marvel Biosciences Sponsors Scientific Meeting on Purines

Feb 18, 2026 08:00AM

Feb 3, 2026 04:30PM

Aug 18, 2025 05:05PM

Apr 30, 2025 07:00AM

Apr 16, 2025 07:00AM

Apr 14, 2025 07:00AM

Mar 17, 2025 07:00AM Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome

Mar 13, 2025 07:00AM

Mar 11, 2025 07:00AM

Jan 16, 2025 07:00AM

Jan 7, 2025 07:00AM

Nov 26, 2024 07:00AM

Nov 21, 2024 07:00AM

Nov 7, 2024 07:00AM Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

Oct 10, 2024 09:00AM

Aug 13, 2024 09:00AM

Jul 24, 2024 09:00AM

Jul 9, 2024 09:00AM

479,842 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All